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Abstract
Background: Epidemiological studies have shown that individuals who regularly consume NSAIDs
have lower rates of mortality associated with colorectal cancer. Because COX-2 inhibitors prevent
tumor growth through some mechanisms, we assessed the effect of JTE-522, a selective COX-2
inhibitor, on pulmonary metastases of colon cancer in a rat model.
Methods: A suspension of 5 × 106 RCN-9 (rat colon cancer cells) was injected into the tail vein
of 24 anesthetized male F344/DuCrj rats. Oral JTE-522 (0, 3, 10, or 30 mg/kg/day) was administered
from the day before RCN-9 injection until the end of the study. Twenty-four days later, the lungs
were removed from sacrificed rats and weighed. Pulmonary metastatic tumors were
microscopically evaluated in the largest cross sections. We also performed immunohistochemical
staining for both COX-2 and VEGF.
Results: JTE-522 dose-dependently decreased lung weight (p = 0.001) and the size of pulmonary
metastatic tumors (p = 0.0002). However, the differences in the number of metastatic tumors
among 4 groups were insignificant. Significant adverse effects of JTE-522 were undetectable.
Immunohistochemical staining showed high levels of both COX-2 and VEGF in pulmonary
metastatic tumors.
Conclusion: JTE-522 dose-dependently decreased the size, but not the number of pulmonary
metastases. COX-2 inhibitors might block metastatic tumor growth, but not actual metastasis.
Selective COX-2 inhibitors might be useful as therapeutic agents that inhibit the growth of
metastatic tumors, as well as the tumorigenesis of colorectal cancer.
Background
Colorectal cancer is a widespread fatal malignancy in the
West [1] and its incidence in Japan is increasing [2]. Epi-
demiological studies have shown that regular doses of
nonsteroidal anti-inflammatory drugs (NSAIDs) are asso-
ciated with lower rates of colorectal polyps, colorectal can-
cer, and colorectal cancer-associated mortality. Waddell
and Loughry initially reported that sulindac decreased the
number of polyps in patients with familial adenomatous
polyposis (FAP) [3]. The largest study of aspirin and colon
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cancer was undertaken by Thun et al. in 1991 [4]. They
found that colon cancer mortality decreased among those
who used aspirin, and that the protective effect was
increased by increasing doses. NSAIDs inhibit prostaglan-
din production mainly by inhibiting cyclooxygenase
(COX) that is expressed as COX-1 and COX-2 isoforms.
Cox is a key enzyme, which converts arachidonic acid to
prostaglandins. COX-1 is constitutively expressed in most
tissues and is thought to be responsible for homeostatic
functions. On the other hand, COX-2 expression is
induced by various factors including cytokines, growth
factors, and tumor promoters [5,6]. Many studies have
indicated that COX-2 expression is associated with both
the carcinogenesis and growth of colon cancer. COX-2 is
overexpressed in 85% of human colorectal cancers [7].
Oshima et al. disclosed that COX-2 gene knockouts and a
COX-2 inhibitor decreased the number of polyps of
apc∆ 716 knockout mice [8]. In addition, several studies
have shown that the selective inhibition of COX-2 reduces
colorectal tumorigenesis in various models of carcinogen-
esis. Reddy et al. found that the COX-2 inhibitor, SC-
58635 (celecoxib), significantly suppressed colonic aber-
rant crypt foci and crypt multiplicity in rats [9]. This sup-
ports the hypothesis that COX-2 inhibitors are
chemopreventive. Kawamori et al. showed that celecoxib
inhibited both the incidence and multiplicity of colon
tumors in a rat model [10], and another study showed
that COX-2 expression in colon cancer cells increased
metastatic potential [11]. We reported that increased
COX-2 levels in human colorectal carcinomas correlated
with both the size and invasiveness of tumors [12]. Tomo-
zawa et al. demonstrated a correlation between COX-2
overexpression and the recurrence of colorectal cancer
[13].
It is well known that colorectal metastasis occurs prima-
rily in the liver and secondarily in the lung [14]. A laparot-
omy is necessary for making experimental model of liver
metastasis in rats, but it is also a stressful event. On the
other hand, it is less invasive to make lung metastasis by
injection of tumor cells into the tail vein of rats. Thus, we
considered that the experimental model of pulmonary
metastasis was appropriate for the evaluation of the real
effect of JTE-522, a selective COX-2 inhibitor, on hema-
togenous metastasis of colon cancer in rats. The aim of
this study was to examine the effect of JTE-522 on hema-
togenous metastasis of colon cancer in a rat model.
Methods
Preparation of JTE-522
The selective COX-2 inhibitor, JTE-522 [15], was sus-
pended in 0.5% carboxymethyl cellulose sodium salt
(Wako Life Science Reagents, Osaka, Japan).
Animals
Twenty-four 4-week-old male F344/DuCrj rats, weighing
50 to 70 g purchased from SLC (Shizuoka, Japan) were
acclimatized for one week before use in this study. The
rats were maintained in an environment with a controlled
temperature (22 to 24°C), humidity (40 to 50%), and
lighting (12 hours light-dark cycle) with free access to tap
water and standard rodent chow (CE-2, Nihon Clea,
Tokyo, Japan).
Tumors
The RIKEN CELL BANK donated the rat colon cancer cell
line, RCN-9, which was established by Inoue et al. after
inbred F344/DuCrj rats were subcutaneously injected
with neutralized 1, 2- dimethylhydrazine (DMH) [16].
The tumor cells were stored at -80°C. After thawing,
tumor cells were washed in phosphate-buffered saline
(PBS) and resuspended in RPMI-1640 (Sigma Chemical
Co., St. Louis, MO) medium containing 10% heat-inacti-
vated fetal bovine serum (FBS; Sigma) and 0.05% penicil-
lin-streptomycin (Sigma). After repeated subculture, cell
viability was assessed by Trypan blue dye exclusion and
the cells were counted using a hemocytometer.
Induction of lung metastases
F344 male rats were anesthetized with ether and then a
tumor suspension containing 5 × 106 RCN-9 cells in 0.4
ml of PBS was injected into the tail vein.
Pulmonary metastases of colon cancer in rats
Twenty-four rats were divided into four groups. Group 1
(control) was not given JTE-522. The other three groups
all orally received daily doses of 3, 10 and 30 mg/kg JTE-
522 (groups 2, 3 and 4, respectively) by gavage from the
day before RCN-9 injection until the end of the study. The
rats were sacrificed 24 days after injection and the lungs
were removed and weighed. After 3-day formalin fixation,
lungs were embedded in paraffin. Paraffin-embedded sec-
tions were cut into 3-µm serial sections, which stained
with hematoxylin and eosin to evaluate the pharmacolog-
ical effects of JTE-522 on pulmonary metastases. The
number and the largest diameter of metastatic tumors
were examined microscopically in the largest sagittal cross
section. The largest metastatic tumor was selected after
measuring the diameter of 10 tumors in each slide.
Immunohistochemistry
Slides were immunohistochemically examined using the
Universal Immuno-enzyme Polymer (UIP). Sections of 3
µm thick were cut from formalin-fixed and paraffin-
embedded blocks of rat tissues. The slides were deparaffi-
nized in xylene, rehydrated through a graded series of eth-
anols and washed with distilled deionized water. Antigen
was retrieved by incubating the sections in 10 mmol/L cit-
rate buffer (pH 6.0) in an autoclave (120°C) for 5BMC Cancer 2005, 5:26 http://www.biomedcentral.com/1471-2407/5/26
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Graphs of pulmonary metastases of rats Figure 1
Graphs of pulmonary metastases of rats. (A) Lung weight of control and JTE-522 treated rats injected with RCN-9 
(group 1, 10.70 ± 0.57 g; group 2, 9.14 ± 0.62 g; group 3, 5.61 ± 0.76 g; group 4, 3.52 ± 0.81 g). JTE-522 significantly and dose-
dependently decreased the lung weight of each group (p = 0.0001). (B) Maximal diameter of metastatic tumors in control and 
JTE-522 treated rats injected with RCN-9 (group 1, 5067 ± 499 µm; group 2, 4233 ± 244 µm; group 3, 2583 ± 211 µm; group 
4; 1990 ± 96 µm). JTE-522 significantly and dose-dependently decreased size of metastases (p = 0.0002). (C) The number of 
metastatic tumors in control and JTE-522 treated rats injected with RCN-9 (group 1, 203 ± 26; group 2, 197 ± 26; group 3, 204 
± 18; group 4, 165 ± 33). Microscopy shows no significant differences in the number of metastases (p = 0.13)
A
B
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minutes. Thereafter, slides were cooled to room tempera-
ture and then washed with distilled deionized water. To
quench endogenous peroxidase activity, slides were
immersed in 3% H2O2 in methanol for 20 minutes. After
a short rinse in phosphate-buffered saline (PBS), non-spe-
cific binding was blocked by incubating the sections in
10% normal goat serum for 10 minutes at room tempera-
ture. Thereafter, the slides were incubated with primary
antibodies directed against COX-2 (rabbit polyclonal,
Cayman Chemical, Ann Arbor, MI; dilution 1:250) for 2
hours or vascular endothelial growth factor (VEGF) (rab-
bit polyclonal, VEGF A-20: sc-152; Santa Cruz Biotechnol-
ogy, Santa Cruz, CA; dilution 1:200) for 1 hour at room
temperature. The slides were washed in PBS (3 × 5 min-
utes) and incubated with secondary antibody (N-
Histofine® Simple Stain MAX PO, Nichirei, Tokyo, Japan)
for 30 minutes at room temperature. After washing in
PBS, color was developed using 3, 3'-diaminobenzidine
tetrahydrochloride (Sigma) in 50 mmol Tris-HCl (pH
7.5) for 5 minutes and counterstaining with 1% Mayer's
hematoxylin. Sections known to show intense immunos-
taining for COX-2 and VEGF were included in each exper-
iment, having been incubated with either primary
antibody or PBS as positive and negative controls, respec-
tively. The positive controls were always obviously stained
and negative controls were never stained.
Evaluation of immunostaining
The specimens immunostained for COX-2 and VEGF were
independently scored by two blinded investigators. Both
the distribution (the percentage of positive cells) and the
intensity of staining were assessed in a semiquantitative
fashion. Sections were scored, according to the method of
Yukawa et al [17]. Both the number of positive cells and
the intensity of staining were evaluated as follows. The
number of positive cells: none, 0; focal (one third of cells
stained), 1; multifocal (two third of cells stained), 2; and
diffuse (most cells stained), 3. The intensity of staining:
none, 0; mild (between 0 and 2), 1; and strong (clearly
identified by × 40 magnification), 2. The score for distri-
bution and intensity were added and graded as follows: 0,
1, and 2: negative; and 3, 4, and 5: positive.
Statistical analysis
The effects of JTE-522 on pulmonary metastasis were ana-
lyzed by the Kruskal-Wallis test and are expressed as
means ± standard deviation. A correlation between COX-
2 and VEGF expression was analyzed by Spearman's rank
test. In all instances, statistical significance was estab-
lished at p < 0.05.
Results
Pulmonary metastases
Each group consisted of 6 rats. JTE-522 significantly and
dose-dependently decreased the weight of the lungs (p =
Removed lungs and the largest cross sections Figure 2
Removed lungs and the largest cross sections. (A) 
Representative lungs of rats injected with RCN-9. Removed 
lungs on the left were those of group 4 (JTE-522: 30 mg/kg/
day); and those on the right were group 1 (control). Surface 
of the lungs of group 1 has more metastatic tumors than that 
of group 4. (B) The largest cross-sections of group 1 (con-
trol) and group 4 (JTE-522: 30 mg/kg/day), which were 
stained with hematoxylin and eosin. The upper slide shows 
the largest cross-section of group 1, and the lower one 
shows that of group 4. Many metastatic tumors are not visi-
ble on the surface.
A
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0.0001, Figure 1A). Cross sections contained many meta-
static tumors that were not visible on the surface (Figures
2). The size of the metastatic tumors was significantly and
dose-dependently decreased (p = 0.0002, Figure 1B),
although the number of metastases did not differ (Figure
1C). JTE-522 appeared to have no significant adverse
effects.
Immunohistochemistry
Immunohistochemical staining showed that both COX-2
and VEGF were expressed at high levels in pulmonary
metastatic tumors of all groups (Figures 3). The large air-
ways and vascular structures were stained for both pro-
teins, as were tumor cells in all groups. However, there
was no correlation between COX-2 score and VEGF score
(p = 0.60, Figure 4). The degree of COX-2 and VEGF
immunohistochemical staining in tumor cells did not sig-
nificantly differ among groups (Table 1).
Discussion
JTE-522 dose-dependently reduced the weight of the lung
with metastases and the size of metastatic tumors. These
observations are consistent with those of other studies of
selective COX-2 inhibitors. In the present study, however,
the number of metastatic lesions determined microscopi-
cally was not reduced by JTE-522, which conflicts with the
earlier findings. Masferrer et al. described the inhibition of
tumor growth and lung metastasis of Lewis Lung carci-
noma in mice by continuous dietary celecoxib (160–3200
ppm) supplied from the date of implantation [18].
Celecoxib at a dose of 160 ppm did not affect the number
and size of lung metastases, but doses between 480 and
3200 ppm reduced the number of metastatic nodules by
>50%. Histopathological analysis revealed that celecoxib
dose-dependently reduced the size of the metastatic lung
tumors. Masferrer et al. evaluated the pharmacological
effects of celecoxib on lung metastasis by counting the
metastatic tumors using a stereomicroscope and by histo-
Immunohistochemical staining for COX-2 and VEGF Figure 3
Immunohistochemical staining for COX-2 and VEGF. A, B, and C show immunohistochemical staining for COX-2 in 
lungs of rats injected with RCN-9. A, group 1 (control group); B and C, group 4 (JTE-522; 30 mg/kg/day). Tumor cells in all 
groups expressed COX-2. Degree of staining between groups 1 and 4 did not differ. Vascular structures (black arrow, B) and 
large airways (black arrow, C) in the rat lung were stained for COX-2. White arrow in C shows tumor cells stained for COX-
2. Original magnification, A and B, ×400, C, ×200. D, E, and F show immunohistochemical staining for VEGF in lungs of rats 
injected with RCN-9. D and E, group 1 (control); F, group 2 (JTE-522; 3 mg/kg/day). Tumor cells of all groups expressed VEGF. 
Degrees of staining between groups 1 and 2 did not differ (D and F). Vascular structures (black arrow, E) and large airways 
(white arrow, F) were stained for VEGF in rat lung. Black arrow in F shows tumor cells stained for VEGF. Original magnifica-
tion, ×400.
A                                             B                  C
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chemical analyses of consecutive lung sections. Tomo-
zawa  et al. investigated the effect of JTE-522 on lung
metastasis of colon cancer in mice [19]. Their study
showed that JTE-522 significantly reduced the number of
metastatic nodules and lung weight. They macroscopi-
cally counted the metastatic tumors on the lung surface.
Our study using cross sections disclosed that many nod-
ules were not visible on the surface and could not be seen
by the naked eye. These observations may indicate that
JTE-522 blocks the growth of metastatic tumors, but does
not inhibit the process of metastasis. On the other hand,
a recent study in vitro, using cancer cell lines preincubated
with celecoxib, suggests that COX-2 is involved in adhe-
sion of cancer cells to vascular endothelium [20]. If the
cancer cells had been pretreated with JTE-522 for an
Immunohistochemical score of COX-2 and VEGF Figure 4
Immunohistochemical score of COX-2 and VEGF. Relation between the immunohistochemical score of COX-2 and 
that of VEGF is shown. The score was defined as positive, if it was 3 or more. The number of each score (COX-2 vs VEGF) 
was as follows: 3 vs 3, 1; 4 vs 4, 8; 4 vs 5, 4; 5 vs 4, 8; and 5 vs 5, 3. Both COX-2 and VEGF were positive in all groups, how-
ever, there was no correlation between COX-2 and VEGF scores (p = 0.60, Spearman's rank test).
Table 1: Immunohistochemical staining score of COX-2 and VEGF.
Group COX-2 Expression Score VEGF Expression Score
Group 1 4.5 ± 0.55 4.0 ± 0.51
Group 2 4.5 ± 0.55 4.0 ± 0.41
Group 3 4.5 ± 0.55 4.0 ± 0.41
Group 4 4.0 ± 0.75 4.0 ± 0.82
p value NS NS
NS: not significantBMC Cancer 2005, 5:26 http://www.biomedcentral.com/1471-2407/5/26
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appropriate period in the present study, it might reduce
the number of the lung metastases.
Here, we immunohistochemically stained COX-2 and
VEGF because some reports indicate that prostaglandins
regulate VEGF expression [21,22] and that COX-2 inhibi-
tors directly affect angiogenesis [23]. Other recent studies
have confirmed the notion that tumor growth and metas-
tasis are dependent on angiogenesis and require the devel-
opment of new vessels [24-26], and that COX-2 is related
to tumor angiogenesis. COX-2 modulates the production
of angiogenic factors derived from colon cancer cells,
while COX-1 regulates angiogenesis in endothelial cells
[27]. COX-2 is also related to tumor angiogenesis in
human colorectal cancer. Cianchi et al. identified a signif-
icant correlation between COX-2 and VEGF, the latter of
which might be one of the most important mediators of
the COX-2 angiogenic pathway [28]. Immunohistochem-
ical staining in the present study revealed parallel COX-2
and VEGF expression that was mainly localized in the
cytoplasm of tumor cells, epithelial cells of the airways,
and vascular structures. These findings may indicate that
COX-2 is involved in the production of VEGF. Further-
more, the present study supports our previous report that
JTE-522 interferes with the growth of metastatic tumors of
colon cancer, due to inhibition of neovascularization
[29]. Our results showed that high levels of COX-2 were
expressed in the groups administered with JTE-522 as well
as in controls. This is consistent with the fact that JTE-522
suppresses not the production, but the activity of COX-2
in prostaglandin biosynthesis [15]. VEGF was also highly
expressed in all groups. One of the reasons may be
hypoxia induced by multiple pulmonary metastases.
Christou et al. reported that hypoxic animals have signifi-
cantly higher VEGF concentrations compared with nor-
moxic controls [30]. On the other hand, these findings
may indicate that VEGF is produced via a pathway, which
does not include COX-2, as well as through a COX-2
pathway.
We reported that COX-2 is related to human colorectal
tumorigenesis. COX-2 mRNA expression is obviously
increased in sporadic adenomas compared with normal
colorectal mucosa and is significantly greater in adenomas
with larger diameters [31]. Additionally, COX-2 expres-
sion and degree of dysplasia are significantly associated in
adenomas [32]. COX-2 levels in human colorectal carci-
nomas are significantly higher in larger tumors and in
those that invade more deeply [12]. We therefore postu-
lated that COX-2 might correlate with metastasis as well as
primary colorectal tumor, because hematogenous metas-
tasis is the key for prognostic factor in colorectal cancer.
The advances in the treatment for metastasis would
improve the prognosis of the patients with colorectal can-
cer. The present study found that JTE-522 dose-depend-
ently suppressed metastatic tumor growth, although the
function to prevent cancer cells from metastasizing might
not be so strong. Our recent report has revealed that
administration of rofecoxib, a selective COX-2 inhibitor,
decreased the number and size of rectal polyps in familial
adenomatous polyposis patients, whereas the relapse of
rectal polyps was seen 3 months after completion of the
treatment [33]. This phenomenon might indicate that
COX-2 inhibitors make colorectal polyps invisible,
although atypical cells still exist microscopically. This is
consistent with the result of the present study.
Recent reports have shown the inhibitory effect of
rofecoxib on liver metastases. Yao et al. demonstrated that
rofecoxib decreased the growth and metastatic potential
of colorectal cancer in mice through multiple mechanisms
[34]. Fenwick et al. reported that refecoxib negatively reg-
ulated angiogenesis in human colorectal cancer liver
metastases [35]. It is considered that COX-2 inhibitors can
be used as therapeutic agents for hematogenous metas-
tases of colorectal cancer.
Conclusion
In conclusion, JTE-522, a selective COX-2 inhibitor, dose-
dependently inhibited the growth of pulmonary metasta-
sis from colorectal cancer in a rat model. Selective COX-2
inhibitors may constitute useful therapeutic agents that
can interfere with the growth of hematogenous metasta-
sis, as well as the tumorigenesis of colorectal cancer.
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